Diabetic Neuropathic Pain – Pipeline Review, 2019

High blood glucose levels can lead to complications that affect the nerves by damaging the blood vessels resulting in severe nerve pain known as diabetic neuropathic pain. Diabetic neuropathy is of four types: peripheral, autonomic, proximal, and focal. Depending on the nerve damage, the symptoms of diabetic neuropathy varies, which includes pain, numbness in legs or feet, problems with the digestive system, urinary tract, blood vessels, and heart. The exact cause of diabetic neuropathic pain is unknown, but factors such as inflammation of nerves caused by an autoimmune response, genetic factors, and smoking & alcohol habits may lead to nerve damage and increase the risk of diabetic neuropathic infection.

Currently, there is no direct cure for diabetic neuropathy, but its progression can be lowered by reducing blood glucose levels. Over-the-counter (OTC) medications like acetaminophen, aspirin, or ibuprofen are used for lowering the pain. Prescription medications such as anti-depressants, anti-seizure, and opioids are used to lower the symptoms caused by diabetic neuropathy.

According to the International Diabetes Federation, it is estimated that by 2045, 629 million people worldwide will suffer from diabetes. The increasing prevalence of diabetes and associated risk factors are boosting the research by pharmaceutical companies and research institutes for developing new treatment options for diabetic neuropathic pain. For instance; DS-5565, which is being studied by Daiichi Sankyo Co., Ltd. is currently in phase-3 clinical trials for the study of safety and efficacy of DS-5565 in patients with diabetic neuropathic pain.

To know how our report can help streamline your business, Speak to Analyst

At present, around 51% of the pipeline candidates for diabetic neuropathic pain are in phase 2 clinical stage. More than half of the studies are sponsored by pharmaceutical companies.

Report Description

The report on ‘Diabetic Neuropathic Pain – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for diabetic neuropathic pain. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for diabetic neuropathic pain.

The report on ‘Diabetic Neuropathic Pain – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• A thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for diabetic neuropathic pain
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for diabetic neuropathic pain
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary